Loading companies…
V
Vaxdyn
Spain · Biotech
Vaxdyn develops vaccines against antimicrobial-resistant bacteria, including its lead candidate K-VAX for Klebsiella pneumoniae and Acinetobacter baumannii.
Product and development
Vaxdyn’s proprietary vaccine platform is designed to address bacterial infections for which antibiotic resistance limits treatment options. Its lead candidate, K-VAX, targets Klebsiella pneumoniae and Acinetobacter baumannii and is ready to enter first-in-human evaluation.
The company is advancing its vaccine from preclinical development toward clinical testing. Its September Series A will fund the first-in-human Phase I trial of K-VAX, so the candidate remains investigational rather than an available vaccine.
- Product focus
- Vaccines against antimicrobial-resistant bacteria
Funding history
0 rounds · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|
Investors
No participants disclosed.
Coverage
Similar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed